Text Size
Trial record 7 of 55 for:    Open Studies | "Prostatic Hyperplasia"
Previous Study | Return to List | Next Study

Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (BPH)

This study is not yet open for participant recruitment.
Verified January 2013 by HistoSonics, Inc.
Sponsor:
Information provided by (Responsible Party):
HistoSonics, Inc.
ClinicalTrials.gov Identifier:
NCT01775488
First received: January 21, 2013
Last updated: January 24, 2013
Last verified: January 2013
History of Changes
  Purpose

The HistoSonics' Histotripsy BPH Device, the Vortx Rx, is a portable ultrasound therapy device. The purpose of this study is to assess and monitor the performance of the Vortx Rx for initial safety and efficacy for the treatment of Benign Prostatic Hyperplasia.


Condition Intervention
Benign Prostatic Hyperplasia (BPH)
 Device: Vortx Rx - Histotripsy BPH Device

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (BPH)

Further study details as provided by HistoSonics, Inc.:

Primary Outcome Measures:
  • Number of participants with adverse events [ Time Frame: Up to 6 months ] [ Designated as safety issue: Yes ]
    • Record and report all adverse events.
    • Determine rate of occurrence of adverse events,serious adverse events and device-related adverse events as a measure of safety and as factors used to determine study success.


Secondary Outcome Measures:
  • Assess initial prostate histotripsy treatment efficacy [ Time Frame: Up to six months ] [ Designated as safety issue: No ]
    1. Change in Lower Urinary Tract Symptoms [LUTS], International Prostate Symptom Score [IPSS], uroflow (Qmax), post-void residual (PVR). Each to be measured at 1, 3 and 6 months post-treatment
    2. Change in prostate parenchymal volume including TRUS and Prostate-Specific Antigen [PSA]. TRUS to be performed at end of treatment and at 6 months post-treatment. PSA to be tested at 6 months post-treatment.


Estimated Enrollment: 20
Study Start Date: March 2013
Estimated Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Vortx Rx - Histotripsy BPH Device
The Vortx Rx, is a portable ultrasound therapy device system that is intended for the treatment of BPH by using very intense, low duty-cycle ultrasound pulses to debulk prostatic tissue.
 Device: Vortx Rx - Histotripsy BPH Device
Non-invasive histotripsy treatment / therapy to be delivered by surgeon using very low duty cycle ultrasound pulses from outside the patient's body. These pulses form a bubble cloud at the focal area within the prostate which mechanically breaks up the cellular structure of the soft tissue. During treatment, a surgeon is able to direct the bubble cloud throughout the targeted volume using controls located on the device console and using the real-time ultrasound for visualization feedback and control of the bubble cloud location.
Other Name: HistoSonics Histotripsy BPH Device

  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Diagnosis of BPH and eligible for endoscopic BPH surgery including Transurethral Resection of the Prostate [TURP], PVP, electrovaporization
  2. Prostate volumes 30 - 80 gm based on transrectal ultrasound
  3. Men ≥ 50 years of age
  4. IPSS symptom score > 15 and IPSS bother score > 2
  5. Baseline peak flow rate Qmax < 12 cc/s on two separate occasions with voided volume at least 150 cc

Exclusion Criteria:

  1. History of prostate or bladder cancer, pelvic radiation, untreated bladder stones, urethral strictures/bladder neck contracture (BNC), renal insufficiency (i.e. creatinine > 1.4)
  2. Neurogenic bladder, Parkinson's disease
  3. Prior treatment for urinary incontinence
  4. Micturition frequency AND urgency. Micturition frequency defined as > 8 micturitions per 24 hours as assessed by a thorough subject history including the question: "On average, how many times do you void during a 24 hour period? // < 4, 5-7, 8 or more." Urgency defined as an uncontrollable urge to void that occurs > 3 per 24 hours as assessed through the subject history/question: "On average, how many times a day do you have an uncontrollable urgency to void? // 0, 1-2, 3 or more?"
  5. Intravesical prostate lobe protrusion > 1 cm on TRUS. Note: this is distinct from lateral lobes protruding up to the bladder such as an intravesical protrusion without median lobe
  6. Active Urinary Tract Infection [UTI] (i.e. must have a screening urinalysis without signs of infection or a negative urine culture)
  7. PVR > 250 at time of enrollment or catheter dependent bladder drainage
  8. History of chronic prostatitis within the last 5 years
  9. Not able to temporarily discontinue aspirin, Coumadin, Plavix and any other anticoagulant at least seven days prior to the time of treatment
  10. History of known bleeding disorders (e.g. von Willebrand disease)
  11. Prior BPH prostate procedures (e.g. Transurethral Microwave Therapy [TUMT], TUNA, water induced thermotherapy, TURP, PVP)
  12. Men with confirmed or suspected malignancy of the prostate based on a digital rectal exam (DRE), prostate biopsy or PSA > 10 ng/mL. Men with free PSA < 25% and with PSA within an age and race-specific range may only be enrolled after a negative biopsy. If a biopsy is required, the subject shall have a six-week waiting period between the biopsy and histotripsy treatment, if he is deemed eligible to participate in the study.
  13. Men interested in future fertility
  14. Declines or unable to provide informed consent
  15. Non-English-speaker
  16. Life expectancy estimated to be less than one year
  17. Unable or unwilling to complete all required questionnaires and follow-up assessments
  18. In the opinion of the investigator, it is not in the subject's best interest to participate in the study.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01775488

Contacts
Contact: Hassan Razvi, MD, FRCSC 519.646.6259 hassan.razvi@sjhc.london.on.ca

Locations
Canada, Ontario
St. Joseph's Hospital Not yet recruiting
London, Ontario, Canada, N6A 4V2
Contact: Hassan Razvi, MD, FRCSC     519.646.6259     hassan.razvi@sjhc.london.on.ca    
Principal Investigator: Hassan Razvi, MD, FRCSC            
Sponsors and Collaborators
HistoSonics, Inc.
Investigators
Principal Investigator: Hassan Razvi, MD, FRCSC The University of Western Ontario, St. Joseph's Hospital
  More Information

No publications provided

Responsible Party: HistoSonics, Inc.
ClinicalTrials.gov Identifier: NCT01775488     History of Changes
Other Study ID Numbers: 01.CP.0.2
Study First Received: January 21, 2013
Last Updated: January 24, 2013
Health Authority: Canada: Health Canada

Keywords provided by HistoSonics, Inc.:
Benign Prostatic Hyperplasia
BPH
LUTS
Vortx Rx
Histotripsy

Additional relevant MeSH terms:
Prostatic Hyperplasia
Hyperplasia
Prostatic Diseases
Genital Diseases, Male
Pathologic Processes

ClinicalTrials.gov processed this record on May 23, 2013